Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
FK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
- Mechanism
- Curator reviewed
Intradialytic hypotension is a most frequent complication of hemodialysis and may contribute to cardiovascular events and high mortality. There is a hypothesis that an increase in adenosine generation during hemodialysis may cause vasodilation and a decrease in cardiac output, which results in systemic hypotension. The A1 receptors, which are reported to be distributed in the ends of sympathetic nerves, suppress the release of catecholamines from the ends of the nerves. Adenosine selectively inhibits contractions of the rabbit portal vein evoked by adrenergic nerve stimulation via activation of an A1 receptor. This means that adenosine could inhibit constriction of peripheral vessels via the A1 receptors in the ends of the nerves. FK352, a highly selective A1 adenosine receptor antagonist, significantly attenuated LPS-induced reductions in renal blood flow and mean arterial pressure. It may restore the adenosine-induced decline in constriction.
- Primary indication
- Investigated for use/treatment in hypertension.Curator reviewed
- Formula / weight
- C23H23N3O3 · 389.455 g/mol (avg)
- Also known as
- 2-((2R)-1-((2E)-3-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)PROP-2-ENOYL)PIPERIDIN-2-YL)ACETIC ACID · 2-PIPERIDINEACETIC ACID, 1-((2E)-1-OXO-3-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)-2-PROPEN-1-YL)-, (2R)-
- Code names
- FK-352
Resolves to
UWTYIJJJSYDUQM-QFQMRYFISA-NSMILESOC(=O)C[C@H]1CCCCN1C(=O)\C=C\C1=C2C=CC=CN2N=C1C1=CC=CC=C1What you can answer from here — as of March 06, 2025
Which drugs share a target with FK352B, and which of those have an active Phase 3 trial?